Observational studyThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
Clinical and epidemiological characteristics and risk factors for mortality in patients with candidemia in hospitals from Bogotá, Colombia.
Observational study in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Neonatal Candidemia in Latin America: Trends, Resistance, and Prevention Strategies (2008-2025).Journal of fungi (Basel, Switzerland) · 2026Review
- Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014-2024).PloS one · 2026Observational
- Genomic epidemiology of Colombian resistantAntimicrobial agents and chemotherapy · 2025Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Molecular Evaluation of the mRNA Expression of theJournal of fungi (Basel, Switzerland) · 2024Article
- Fungemia in Hospitalized Adult Patients with Hematological Malignancies: Epidemiology and Risk Factors.Journal of fungi (Basel, Switzerland) · 2023Article
- Candidal Infections in the Neonatal Intensive Care Unit: A Retrospective Observational Study.Sisli Etfal Hastanesi tip bulteni · 2023Article
- Risk Factors for Mortality in Colombian Patients with Candidemia.Journal of fungi (Basel, Switzerland) · 2021Article
- Evaluation of Identification and Susceptibility forInternational journal of microbiology · 2021Article
- A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China.Antimicrobial resistance and infection control · 2020Observational
- Candidemia in ColombiaBiomedica : revista del Instituto Nacional de Salud · 2020Article
- Clinical spectrum and factors impacting outcome of Candida auris: a single center study from Pakistan.BMC infectious diseases · 2019Article
- European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute breakpoints-the only point that matters in candidemia?Journal of thoracic disease · 2019Article
- The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Observational
- Burden of Fungal Infections in Colombia.Journal of fungi (Basel, Switzerland) · 2018Article
- Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers.Journal of fungi (Basel, Switzerland) · 2017Review
- Candidemia in the Neonatal Intensive Care Unit: A Retrospective, Observational Survey and Analysis of Literature Data.BioMed research international · 2017Article
- Article
- Resistance Surveillance in Candida albicans: A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital.PloS one · 2016Article
- Inhibition of nucleic acid biosynthesis makes little difference to formation of amphotericin B-tolerant persisters in Candida albicans biofilm.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infection by Candida species has a high mortality in Latin American countries. The aim of this study was to describe the characteristics of patients with documented bloodstream infections caused by Candida species in third level hospitals and determine the risk factors for in-hospital-mortality.
methodsPatients from seven tertiary-care hospitals in Bogotá, Colombia, with isolation of a Candida species from a blood culture were followed prospectively from March 2008 to March 2009. Epidemiologic information, risk factors, and mortality were prospectively collected. Isolates were sent to a reference center, and fluconazole susceptibility was tested by agar-based E-test. The results of susceptibility were compared by using 2008 and 2012 breakpoints. A multivariate analysis was used to determinate risk factors for mortality.
resultsWe identified 131 patients, with a median age of 41.2 years. Isolates were most frequently found in the intensive care unit (ICU). Candida albicans was the most prevalent species (66.4% of the isolates), followed by C. parapsilosis (14%). Fluconazole resistance was found in 3.2% and 17.6% of the isolates according to the 2008 and 2012 breakpoints, respectively. Fluconazole was used as empirical antifungal therapy in 68.8% of the cases, and amphotericin B in 22%. Hospital crude mortality rate was 35.9%. Mortality was associated with age and the presence of shock at the time of Candida detection. Fluconazole therapy was a protective factor for mortality.
conclusionsCandidemia is associated with a high mortality rate. Age and shock increase mortality, while the use of fluconazole was shown to be a protective factor. A higher resistance rate with new breakpoints was noted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.